Tuesday, June 26, 2018 5:16:57 PM
http://www.rmsmedicalproducts.com/wp-content/uploads/2018/06/repr-1q18-presentation.pdf
Additionally some drugs that were traditionally delivered by IV, can now be self administer at home via the RMS home infusion system. This is possible because of the new administration set with the patent pending needles.
There are many sexier technologies but REPR is a small company and has no long term debt. The company can finance its growth without issuing more shares. I expect the company will eventually be bought out at two or more times the current share price.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM